FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia

Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication, Ingrezza (valbenazine) capsules, for the treatment of ... Read More